Tianjin Key Laboratory of Metabolic Diseases, approved in 2015 by Tianjin Municipal Science and technology bureau (formerly known as Tianjin municipal Science and Technology Commission), relies on the National Key Cultivation Disciplineof Endocrineand Metabolic diseases in Tianjin Medical University. The laboratory is compassed of severalunits including Tianjin Institute of Endocrinology, TianjinMetabolic Disease Hospital, Department of Physiology and Pathophysiology of Basic Medical College and Department of Endocrinology of Tianjin General Hospital. Professor Yi zhu appointed to the first term director of the laboratory is one of the principalscientists of the National Key Basic Research Development Plan (also known as “973” programs of Ministry of Science and Technology of the People’s Republic of China). Professor Guang Ning, Academician of China Academy of Engineering, Shanghai Jiaotong University Ruijin Hospital,was invited to be chairman of academic committee of the laboratory in 2015.
The purpose of laboratory construction aiming at international frontier topics of basic medical researchis to explore the key molecular mechanisms of pathogenesis and development of metabolic diseases, mainly focus on diabetes mellitus, lipid metabolic disorders and metabolic osteopathy. On the premise of following the national medium and long-term development strategic plan of China, the laboratory conducts precise studies on prevention and treatment of metabolic diseases, and provides reliable theoretical support for clinical innovation of diagnosis and treatment.
The laboratory condensatesthree research directions: pathogenesis of diabetes mellitus and its complications, pathogenesis of diseases related to lipid metabolism disorders, and bone tissue cells development and regulatorymechanisms of osteoporosis.
Since 2016, the Laboratory has obtained 51 national-level foundations including 9 key projects of the National Natural Science Foundation. The lab has also finicallysupported by 30 research foundations in provincial- and ministerial-level. The total research fund is more than 43million RMB. The laboratory has published 163 peer-reviewed papers in SCI journals (Only the first or communication author's papers are counted). One paper has published in Nature (IF: 45,719). 4 papers have published in the journal with IF between 10 to 20, and 32 papers published in the journals with IF between 5 to 10, respectively. 2 awards of Science and Technology have been given by the Tianjin Municipal Science and technology bureau. 3 honorary awards to endemic diseases investigators have been obtained by the research group of thyroid diseases. Besides, the lab was authorized to a national invention patent.
Yi Zhu, MD, Professor
Dept Physiology and Pathophysiology,
Vice President, Tianjin Medical University
Tianjin, 300070 China
Tel.：+86 22-8333-6665 (O);+86 18920966278 (Cell);
Education and Employment:
B.S. in Medicine in 1983 and M.S. in 1986 from Xi’an Medical University; M.D. in 1993 from University of Lausanne. Postdoctoral training 1993-1997 at New York Medical College and University of California, Riverside; Research Assistant Professor 1998-2003 in University of California, Riverside, Division of Biomedical Sciences; Professor in Physiology since 10/2003 at Peking University Health Sciences Center; From 2012, Vice President in Tianjin Medical University. Dr. Zhu has published 110 articles in peer-reviewed journals, including PNAS, ATVB, Circ Res and Circulation. He is the Chief Scientist in National Major Research Grant “973” Plan; he is also funded a key grant by NSFC. He is the Chairman of Chinese Section, ISHR; the editorial board in many scientific journals, including Arterio Thromb Vasc Biol; J Diabetes.
Research Interests: Signaling in endothelial activation and mechanism of Atherogenesis; Role of homodynamic forces in the focal feature of atherosclerosis.
Represented Recent Publications:
1.Li B, He J, Lv H, Liu Y, Lv X, Zhang C, Zhu Y*, Ai D*. c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow. J Clin Invest.2019;129:1167-79.
2.Wang L, Luo JY, Li B, Tian XY, Chen LJ, Huang Y, Liu J, Deng D, Lau CW, Wan S, Ai D, Mak KK, Tong KK, Kwan KM, Wang N, Chiu JJ, Zhu Y*, Huang Y*. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. Nature2016; 540, 579–82.
3.Yao L, Wang C, Zhang X, Peng L, Liu W, Zhang X, Liu Y, He J, Jiang C, Ai D*, Zhu Y*.Hyperhomocysteinemia activates the aryl hydrocarbon receptor/CD36 pathway to promote hepatic steatosis in mice. Hepatology 2016;64:92-105.
4.Sun X, Fu Y, Gu M, Zhang L, Li D, Li H, Chien S*, Shyy JY*, Zhu Y*. Activation of integrin α5 mediated by flow requires its translocation to membrane lipid rafts in vascular endothelial cells. Proc Natl Acad Sci U S A 2016. 113:769-74.
5.Zhang D, Xie X, Chen Y, Hammock BD, Kong W, Zhu Y. (2012) Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Circ Res. 2012;110:808-17.
6.Fu Y, Hou Y, Fu C, Gu M, Li CH, Shyy JY, Zhu Y. A novel mechanism of T-lymphocyte and endothelial activation by shear stress -- the role of ecto-ATP synthasechain. Circ Res. 2011;108:410-7.